The Glow Protocol
Peptide Stack for Skin Health, Recovery and Cellular Radiance
The glow protocol is a medically supervised peptide stack combining GHK-Cu, BPC-157, TB-500, and NAD+ support to stimulate collagen synthesis, modulate inflammation, and restore cellular energy from within. These compounds are delivered via subcutaneous injection or IV infusion, reaching dermal fibroblasts and connective tissue directly rather than acting at the skin’s surface. The evidence is real but uneven: GHK-Cu holds human-model clinical data, while BPC-157 and TB-500 remain primarily preclinical as of 2026.
Key takeaways
- GHK-Cu (Copper Tripeptide-1) stimulates collagen I and III synthesis in fibroblast models, with peer-reviewed data published in Cosmetics (Pickart and Margolina, 2018; PMC6073405).
- BPC-157 and TB-500 are studied for tissue repair and anti-inflammatory effects in animal models; direct human trial evidence in aesthetic applications remains limited as of 2026.
- BPC-157 was removed from the FDA’s 503A compounding list in 2023, meaning most US compounding pharmacies cannot legally prepare it for individual patients.
- TB-500 (Thymosin Beta-4) appears on the WADA prohibited list (a disclosure your provider should address if you compete in tested sports).
- Full protocol outcomes typically require 8-12 weeks; standard cycling is 4-8 weeks on, followed by 2-4 weeks off.
Before you start All peptide protocols require a physician evaluation before initiation. Individuals with active cancer, a history of hormone-sensitive tumors, pregnancy, immunosuppressive medication use, or uncontrolled chronic illness should not start the glow protocol without detailed medical clearance from a licensed provider.
What’s in the glow protocol: peptide compounds, mechanisms and evidence
The glow protocol is a multi-compound peptide stack, not a single molecule. Each component targets a distinct biological pathway; the stack rationale is that coordinated signaling across collagen synthesis, inflammation modulation, and mitochondrial energy outperforms any individual compound used alone.
| Compound | Classification | Primary mechanism | Target tissue | Evidence tier | Delivery route |
|---|---|---|---|---|---|
| GHK-Cu | Signal peptide + copper carrier | Stimulates fibroblast production of collagen I/III, elastin, GAGs | Dermis, connective tissue | Tier 1 (human model data) | Topical 1-3% / injectable |
| BPC-157 | Synthetic peptide (gastric origin) | Promotes angiogenesis, tendon and gut tissue repair | Muscle, tendon, gut | Tier 2 (preclinical only) | Subcutaneous injection |
| TB-500 | Thymosin Beta-4 analog | Regulates actin polymerization, promotes cell migration and wound healing | Muscle, skin, cardiac tissue | Tier 2 (preclinical only) | Subcutaneous injection |
| NAD+ | Coenzyme / metabolic cofactor | NAMPT pathway activation, mitochondrial ATP synthesis, SIRT1 activation | Mitochondria, systemic | Tier 2 (limited human data) | IV infusion / oral NMN or NR |
| Glutathione | Antioxidant tripeptide | Neutralizes reactive oxygen species; at high IV doses, may inhibit tyrosinase | Systemic / skin | Tier 2 (limited human data) | IV infusion / topical |
GHK-Cu (Copper Tripeptide-1) is the lead compound in the glow protocol and carries the strongest evidence base. Pickart and Margolina (2018, PMC6073405) reported that GHK-Cu stimulates fibroblast synthesis of collagen I and III, elastin, and glycosaminoglycans (the structural proteins that give skin integrity and volume). Topical GHK-Cu at concentrations of 1-3% is the most studied delivery route. Injectable GHK-Cu is available through compounding pharmacies under physician prescription. Injectable-specific human skin trials have not yet been published.
BPC-157 is a 15-amino acid synthetic peptide derived from a gastric protein sequence. Preclinical rodent studies show BPC-157 promotes angiogenesis, tendon repair, and gut barrier integrity. BPC-157 was removed from the FDA’s 503A compounding list in 2023. Most US compounding pharmacies cannot legally prepare it for individual patients. Clinical access under 503B outsourcing facilities is possible in specific institutional circumstances, always under licensed physician supervision.
TB-500 (Thymosin Beta-4) regulates actin polymerization, a process central to cell migration and wound healing. Maar et al. (2021, PMC8228050) documented Thymosin Beta-4’s regenerative role in reducing inflammatory markers and promoting tissue repair in animal models. TB-500 and related thymosin peptides appear on the WADA prohibited list. Clients who compete in tested sports must disclose use to their sports organization and review eligibility with a sports medicine physician.
NAD+ support targets nicotinamide adenine dinucleotide, a coenzyme that declines with age and is required for mitochondrial ATP production and SIRT1 activation. IV NAD+ infusions and oral precursors, NMN and NR, are the two primary delivery approaches. Human trial data specific to skin and aesthetic outcomes from NAD+ IV infusion protocols remain limited. Mitochondrial energy improvement is the primary documented benefit in the published literature.
Glutathione is the body’s primary intracellular antioxidant tripeptide. At IV doses used in aesthetic protocols, glutathione may inhibit tyrosinase, an enzyme involved in melanin synthesis. Randomized controlled trial evidence for skin-specific aesthetic outcomes from glutathione IV in healthy, non-deficient individuals remains limited as of 2026.
PeptideRx rates the evidence for GHK-Cu in collagen stimulation and fibroblast activation as Grade B. PeptideRx rates the evidence for BPC-157, TB-500, NAD+ IV, and glutathione in aesthetic and recovery applications as Grade C, reflecting predominantly animal model data or limited, non-randomized human studies.
How the glow protocol benefits skin, recovery and energy
The glow protocol targets three distinct biological domains: structural skin support through collagen and matrix synthesis, tissue repair through anti-inflammatory and cell migration signaling, and cellular energy through mitochondrial pathway restoration.
Key takeaways for this section
- GHK-Cu stimulates fibroblast production of collagen I and III, which decline by roughly 1% per year after age 25 (Pickart and Margolina, 2018, PMC6073405).
- BPC-157 and TB-500 modulate inflammatory cytokine pathways and promote cell migration in preclinical models; human aesthetic data are not yet available.
- NAD+ restoration via IV infusion is associated with improved mitochondrial ATP output in aging models; energy improvement may appear within 2-4 weeks of consistent use.
- Glutathione IV at aesthetic doses may reduce oxidative stress and modulate melanin synthesis through tyrosinase inhibition.
Skin structure and collagen synthesis. GHK-Cu signals dermal fibroblasts to produce collagen I and III, elastin, and glycosaminoglycans (GAGs). Collagen production peaks in the mid-20s and declines by approximately 1% per year thereafter (Pickart and Margolina, 2018, PMC6073405). At 1-3% topical concentrations, GHK-Cu has demonstrated fibroblast-activating effects in laboratory models. Injectable delivery is expected to increase systemic bioavailability, though injectable-specific human skin trials have not yet been published.
Anti-inflammatory effects and tissue repair. BPC-157 and TB-500 target inflammatory signaling pathways in preclinical models. Maar et al. (2021, PMC8228050) documented Thymosin Beta-4 reducing inflammatory markers and promoting regenerative cell activity in animal tissue repair models. Whether these mechanisms translate with equivalent magnitude in human aesthetic contexts remains under investigation as of 2026.
Cellular energy and mitochondrial function. NAD+ is required for mitochondrial electron transport chain activity, which generates ATP, the cell’s primary energy currency. NAD+ levels decline measurably with age. IV infusion protocols are designed to restore intracellular NAD+ availability more rapidly than oral precursors. Energy-related improvements are the most consistently reported subjective outcome in clinical practice.
Skin brightening and oxidative stress reduction. Glutathione neutralizes reactive oxygen species that accumulate from UV exposure, pollution, and metabolic activity. At IV doses used in aesthetic protocols, glutathione may inhibit tyrosinase and modulate melanin synthesis pathways. This mechanism is biologically plausible; robust randomized controlled trial evidence in healthy aesthetic clients remains limited.
The glow protocol for post-procedure recovery
Post-procedure recovery is the highest-value clinical application of the glow protocol, and it is entirely absent from competitor content.
Aesthetic procedures including microneedling, ablative laser resurfacing, and chemical peels create controlled dermal wounds to stimulate natural healing cascades. The glow protocol is theorized to amplify this healing response by delivering signaling molecules during the period of peak biological demand. GHK-Cu has direct mechanistic relevance: its fibroblast-stimulating activity may accelerate re-epithelialization and collagen deposition during the post-procedure repair window. BPC-157 and TB-500 target the inflammatory phase of wound healing, which may shorten visible redness and downtime in preclinical models.
Protocol timing is clinician-determined. Most practitioners who administer the glow protocol in post-procedure contexts initiate peptide administration within 24-48 hours following the procedure. The exact timing, compound selection, and dosing must be individualized by the administering physician based on procedure type, skin condition, and patient history. No published human clinical trial has specifically studied the glow protocol in combination with microneedling or laser resurfacing; the rationale is mechanistic, not trial-confirmed.
Important: The post-procedure application of the glow protocol is a clinician-directed, individualized intervention. No published randomized controlled trial has evaluated this combination. Confirm your provider’s protocol rationale and obtain informed consent documentation before proceeding.
How to use the glow protocol: administration, dosing and cycling
Injectable delivery is the standard clinical route for the glow protocol. Route determines bioavailability and which biological targets the compounds can reach.
| Administration route | Compounds | Bioavailability | Supervision required |
|---|---|---|---|
| Subcutaneous injection | BPC-157, TB-500, GHK-Cu (injectable) | High (systemic distribution) | Licensed physician |
| IV infusion | NAD+, Glutathione | High (direct systemic) | Licensed physician or RN |
| Topical serum | GHK-Cu (1-3%) | Surface and upper dermis only | None required |
| Oral (NMN or NR) | NAD+ precursors | Moderate (subject to digestive metabolism) | Physician guidance recommended |
Subcutaneous injection is the standard delivery route for BPC-157, TB-500, and injectable GHK-Cu. Parenteral delivery bypasses digestive degradation, allowing bioactive peptides to enter circulation intact. The Cleveland Clinic and academic medical centers document this pharmacokinetic advantage in the context of injectable peptide therapy.
IV NAD+ infusions are administered in a clinical setting under nursing supervision; sessions typically run 1-3 hours depending on dose and individual tolerance. Topical GHK-Cu serum at 1-3% concentration is the only glow protocol component that does not require medical administration. Topical application is used as a complementary adjunct to injectable protocols, not as a primary replacement.
Clinician-reported dosing ranges (note: the following reflects clinician-reported protocol ranges, not FDA-approved prescribing information; all dosing must be individualized and supervised by a licensed provider):
| Compound | Dose range | Frequency | Source basis |
|---|---|---|---|
| GHK-Cu injectable | 1-3 mg per injection | 3-5 times per week | Clinician-reported |
| BPC-157 | 250-500 mcg per injection | Daily (where 503B access applies) | Clinician-reported |
| TB-500 | 2-2.5 mg per injection | Twice weekly (loading); reduced for maintenance | Clinician-reported |
| NAD+ IV | 250-500 mg per infusion | Once weekly | Clinician-reported |
| Glutathione IV | 600-1,200 mg per infusion | Once weekly | Clinician-reported |
Glow protocol cycling follows an on/off structure to prevent receptor desensitization and allow natural pathway recovery. Most practitioners use a 4-8 week active cycle followed by a 2-4 week rest period. BPC-157 protocols commonly run 4-6 weeks on, 2-4 weeks off. TB-500 often uses a loading phase during weeks 1-4, followed by a reduced maintenance schedule. Reassessment with your prescribing physician at each cycle end is the clinical standard. Dosing is adjusted based on response, labs, and tolerance.
Safety, side effects and FDA regulation of the glow protocol
The glow protocol carries a real side effect and regulatory profile. Full transparency on both is necessary before starting.
Common side effects associated with injectable peptide protocols include injection site reactions (localized redness, swelling, and mild bruising), transient headache, and mild nausea following IV infusions. These are generally self-limiting and resolve without treatment. Published side effect data for the glow protocol as a combined stack are not available; individual compound safety data from preclinical and limited human studies form the current evidence base. Your provider should review each compound’s safety profile with you individually before initiation.
The angiogenesis concern and BPC-157. BPC-157 promotes angiogenesis (new blood vessel formation) in preclinical animal models. The theoretical concern is that pro-angiogenic signaling could, in principle, support tumor vascularization in individuals with existing malignancy. No published human study has established a direct causal link between BPC-157 administration and cancer progression. The preclinical signal is sufficient, however, to list active cancer and a history of hormone-sensitive tumors as firm contraindications in clinical practice.
Contraindications for the glow protocol include:
- Active cancer or a history of hormone-sensitive tumors (due to theoretical pro-angiogenic activity of BPC-157)
- Pregnancy or breastfeeding
- Current use of immunosuppressive medications, including post-transplant regimens
- Uncontrolled chronic illness without physician clearance
- Any condition involving pathological angiogenesis
Legal status (2026): BPC-157 was removed from the FDA’s 503A compounding list in 2023. Most US compounding pharmacies cannot legally prepare it for individual patients. Some 503B outsourcing facilities may supply it under specific institutional circumstances. TB-500 (Thymosin Beta-4) and related peptides appear on the WADA prohibited list. All compounded peptide formulations in the glow protocol must be administered under licensed medical supervision. No component of the glow protocol is FDA-approved for cosmetic or aesthetic indications.
Sourcing quality matters in compounding contexts. Peptides should be obtained only from GMP-certified compounding pharmacies that provide third-party purity and potency testing documentation for each batch. Gray market online sources (websites that sell injectable peptides without a prescription) operate outside regulatory oversight and carry unquantifiable contamination and sterility risks.
Learn more about how to verify a compounding pharmacy’s credentials and what quality documentation to request before starting any injectable peptide protocol.
The bottom line
The glow protocol is a medically supervised multi-peptide stack, not a consumer skincare product. GHK-Cu carries the strongest evidence of the five compounds, with human-model clinical data supporting fibroblast-driven collagen synthesis. BPC-157, TB-500, NAD+, and glutathione rely primarily on preclinical data that has not yet been confirmed in dedicated human aesthetic trials.
Regulatory complexity is real: BPC-157 cannot be legally prepared by most US compounding pharmacies, and TB-500 is prohibited under WADA rules. If you are considering the glow protocol, the starting point is a consultation with a licensed physician who can review your full medical history, assess your goals against the available evidence, and source any compounded peptides from a verified, GMP-compliant facility.
Frequently asked questions
How long does the glow protocol take to show results?
Improvement timelines range from 2-4 weeks for NAD+ energy effects to 8-12 weeks for tissue repair outcomes. GHK-Cu skin texture and firmness changes are typically reported at 4-8 weeks. Deeper tissue repair outcomes from BPC-157 and TB-500, based on preclinical model timelines, often require 8-12 weeks of consistent protocol use. Your physician should track progress and adjust dosing at each cycle end.
Can I combine the glow protocol with topical skincare or supplements?
Yes, with physician review. The glow protocol is frequently combined with GHK-Cu topical serum (1-3%), glutathione IV, and foundational supplements including omega-3 fatty acids, vitamin D, and oral collagen peptides. No known contraindications exist between the glow protocol and standard topical skincare routines. Disclose every supplement and medication to your administering clinician before starting, as interactions are compound-specific.
Is BPC-157 still legal to obtain in the USA in 2026?
No, not through standard 503A compounding routes. BPC-157 was removed from the FDA’s 503A compounding list in 2023, meaning most US compounding pharmacies cannot legally prepare it for individual patients. Some 503B outsourcing facilities may supply it under specific institutional circumstances. Any use must occur under licensed medical supervision. Self-sourced BPC-157 from online vendors carries significant purity, sterility, and legal risks.
Who should not use the glow protocol?
No. The glow protocol is not appropriate for individuals with active cancer or a history of hormone-sensitive tumors, those who are pregnant or breastfeeding, or individuals on immunosuppressive medications. The pro-angiogenic activity of BPC-157 in preclinical models is the primary driver of the cancer contraindication. Disclose your full medical history and all current medications to your prescribing physician before starting.
What is the difference between a glow peptide injection and a topical serum?
Injectable delivery achieves systemic bioavailability and reaches dermal fibroblasts and connective tissue directly. Topical GHK-Cu serum at 1-3% concentration acts at the stratum corneum and upper dermis only. For the full compound profile of the glow protocol, injectable administration is the clinical standard; topical GHK-Cu is used as a complementary adjunct, not a standalone replacement.
Is the glow protocol the same as the peptide glow stack or glow peptide therapy?
Yes. Glow protocol, glow peptide stack, peptide glow stack, and glow peptide therapy are interchangeable terms used across clinics and providers for the same medically supervised multi-peptide approach targeting skin health, recovery, and cellular energy. Compound composition and delivery standards are what matter clinically, not the label your clinic uses.
Considering the glow protocol? Speak with a licensed physician who can review your labs, assess whether the evidence supports your specific goals, and source any compounded peptides from a GMP-compliant pharmacy.
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. PMC6073405.
- Maar K, Hetenyi R, Maar S, et al. Utilizing developmentally essential secreted peptides such as thymosin beta-4 to remind the adult organs of their embryonic gene activation patterns: new directions in anti-aging regenerative therapies. Cells. 2021;10(6):1343. PMID: 34071887. PMC8228050.
- National Institutes of Health. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22:119-141.
- U.S. Food and Drug Administration. 503A compounding pharmacies: bulk drug substance list. Updated 2023.
- World Anti-Doping Agency. Prohibited List 2026. WADA; 2025.
Disclaimer: PeptideRx provides physician-reviewed educational content about peptide therapy. PeptideRx does not provide medical advice, diagnosis, or treatment. The peptides described in the glow protocol are not FDA-approved for human therapeutic use in cosmetic or aesthetic indications. All dosing information reflects published research protocols and clinician-reported ranges, not prescribing recommendations. Consult a licensed healthcare provider before making any decisions about peptide therapy. Content medically reviewed April 2026. Evidence grading criteria are working definitions pending formal review.